Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 7,455 matching trials from the live ClinicalTrials.gov search.

Filters: Denver, Colorado Clear all

Conditions: Ganglioneuroblastoma, Recurrent Neuroblastoma
Interventions: Dinutuximab, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Sargramostim, Temozolomide, Temsirolimus; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 136
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Downey, California + 106 more

Conditions: Influenza, Human
Interventions: Quadrivalent influenza modRNA vaccine, Quadrivalent influenza vaccine; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 45,789 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 263
States / cities: Athens, Alabama • Birmingham, Alabama • Dothan, Alabama + 192 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec, insulin glargine; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 50 Years and older
Enrollment: 7,637 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 267
States / cities: Birmingham, Alabama • Montgomery, Alabama • Gilbert, Arizona + 209 more

Conditions: Alzheimer's Disease
Interventions: Solanezumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 98
States / cities: Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 80 more

Conditions: CCND1 Gene Amplification, CCND2 Gene Amplification, CCND3 Gene Amplification, CDK4 Gene Amplification, Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
Interventions: Docetaxel, Laboratory Biomarker Analysis, Palbociclib; Drug · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1065
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 659 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, Canagliflozin, Sitagliptin, Metformin immediate release; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,284 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 45
States / cities: Little Rock, Arkansas • Fountain Valley, California • National City, California + 42 more

Conditions: Normal Hepatic Function, Impaired Hepatic Function
Interventions: LDK378; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Lakewood, Colorado • DeLand, Florida • Miami, Florida + 2 more

Conditions: Elevated High-sensitivity C-Reactive Protein (hsCRP)
Interventions: Rosuvastatin, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 50 Years and older
Enrollment: 17,802 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 431
States / cities: Birmingham, Alabama • Calera, Alabama • Columbiana, Alabama + 428 more

Conditions: Rotator Cuff Syndrome
Interventions: InSpace sub-acromial tissue spacer system, Partial repair of rotator cuff; Device · Procedure
Lead sponsor: OrthoSpace Ltd.; Industry
Eligibility: 40 Years to 100 Years
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 18
States / cities: Van Nuys, California • Denver, Colorado • Fort Lauderdale, Florida + 12 more

Conditions: HIV Infections, Sexually Transmitted Diseases
Interventions: Video-based HIV/STD prevention intervention; Device
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: Not listed
Enrollment: 45,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2009
U.S. locations: 4
States / cities: Long Beach, California • San Francisco, California • Denver, Colorado + 1 more

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Juvenile Myelomonocytic Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome Post Cytotoxic Therapy, Myeloid Leukemia Associated With Down Syndrome
Interventions: Biospecimen Collection; Procedure
Lead sponsor: PedAL BCU, LLC; Other
Eligibility: Up to 22 Years
Enrollment: 960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 164
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 133 more

Conditions: Lymphoma
Interventions: carmustine, cyclophosphamide, etoposide, mesna, peripheral blood stem cell transplantation; Drug · Procedure
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 21 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2007
U.S. locations: 206
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more

Conditions: Psoriatic Arthritis
Interventions: AIN457 6 mg/kg i.v., Placebo, AIN457 3 mg/kg; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 31
States / cities: Birmingham, Alabama • Fountain Valley, California • Fullerton, California + 28 more

Conditions: T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Interventions: WU-CART-007; Biological
Lead sponsor: Allotera Therapeutics; Industry
Eligibility: 6 Months and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 16
States / cities: Duarte, California • Los Angeles, California • Denver, Colorado + 12 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Adagrasib, Pembrolizumab, Carboplatin, Pemetrexed, Placebo, Cisplatin; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 46
States / cities: Birmingham, Alabama • Springdale, Arkansas • Fullerton, California + 42 more

Conditions: Lung Cancer
Interventions: adjuvant therapy, diagnostic thoracoscopy, therapeutic thoracoscopy, video-assisted surgery, radiation therapy; Procedure · Radiation
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2005
U.S. locations: 13
States / cities: Denver, Colorado • Des Moines, Iowa • Boston, Massachusetts + 8 more

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: irinotecan hydrochloride; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 21 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 45
States / cities: Little Rock, Arkansas • Duarte, California • La Jolla, California + 38 more

Conditions: HIV Infections
Interventions: fosamprenavir, COMBIVIR, ritonavir, TRIZIVIR; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 13 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 13
States / cities: Little Rock, Arkansas • Long Beach, California • Newport Beach, California + 8 more

Conditions: Obesity
Interventions: Retatrutide, Tirzepatide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 40
States / cities: Tempe, Arizona • Newport Beach, California • San Diego, California + 35 more

Conditions: Cystic Fibrosis
Interventions: tauroursodeoxycholic acid, ursodiol; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2001
U.S. locations: 2
States / cities: Denver, Colorado • Cincinnati, Ohio

Conditions: HIV Infections
Interventions: Pravastatin sodium, Simvastatin, Atorvastatin calcium, Ritonavir, Nelfinavir mesylate, Saquinavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2002
U.S. locations: 13
States / cities: Los Angeles, California • San Francisco, California • Stanford, California + 10 more

Conditions: Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions: Cyclophosphamide, Cyclosporine, Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion, Fludarabine Phosphate, Mycophenolate Mofetil, Thiotepa, Total-Body Irradiation, Umbilical Cord Blood Transplantation; Drug · Biological · Radiation + 1 more
Lead sponsor: Nohla Therapeutics, Inc.; Industry
Eligibility: 6 Months to 65 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 8
States / cities: Duarte, California • Palo Alto, California • Denver, Colorado + 5 more

Conditions: Cystic Fibrosis
Interventions: AZLI 75 mg two times a day (BID)/three times a day (TID), Placebo two times a day (BID)/three times a day (TID); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 6 Years and older
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 56
States / cities: Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 50 more

Conditions: Contraception
Interventions: Levonorgestrel 52 MG Intrauterine System; Drug
Lead sponsor: University of Utah; Other
Eligibility: 16 Years to 35 Years · Female only
Enrollment: 1,404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 8
States / cities: San Jose, California • Denver, Colorado • Chicago, Illinois + 5 more

Search by objective public record fields.

Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma

A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older

A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events

A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease

Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)

Effect of Hepatic Impairment on LDK378 Pharmacokinetics

JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events

A Pivotal Study to Assess the InSpace™ Device for Treatment of Full Thickness Massive Rotator Cuff Tears

Video-based Intervention Study to Prevent HIV/Sexually Transmitted Diseases (STDs) Among STD Clinic Patients

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's Lymphoma

Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis

A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Video-Assisted Surgery Followed by Radiation Therapy in Treating Patients With Stage I Non-small Cell Lung Cancer and Poor Heart and Lung Function

Irinotecan in Treating Children With Refractory or Advanced Solid Tumors Who Are Receiving Anticonvulsants

Study to Explore Safety And Tolerability of Fosamprenavir With or Without Ritonavir in Combination With TRIZIVIR or COMBIVIR

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic Fibrosis

A Study on Possible Interactions Between Protease Inhibitors (Anti-HIV Drugs) and Drugs Which Lower the Level of Fat in Your Blood

Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa

Levonorgestrel 52 mg IUD for Emergency Contraception and Same-Day Start